Newsletter

PRESS RELEASES

3 June 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Executive Changes

30 May 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Notice of Annual General Meeting of Shareholders

30 April 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics has published its Annual Report

26 April 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting

27 March 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting

28 February 2024 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Renews CHF 50 million Share Subscription Facility

22 November 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces CEO Transition

15 September 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update

23 June 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement

16 June 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement

28 April 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders

5 April 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Executive Leadership Team Change

4 April 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders

16 March 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe

15 March 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA™ 

8 February 2023 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Provides an Update on its Financing Strategy

14 December 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics to Participate in January Investor Meetings

13 December 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Issuance of Shares from Authorized Capital

8 December 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Executive Leadership Team Changes

14 October 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer

10 October 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Announces U.S. Launch of PKU GOLIKE

6 October 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S.

15 September 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports Half-Year 2022 Results and Provides Corporate Update

12 September 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum

17 August 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access

21 July 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F

23 May 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Expands U.S. Commercial Team

9 May 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics to Participate in Industry and Investor Conferences in May

15 September 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports Half-Year 2022 Results and Provides Corporate Update

12 September 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum

17 August 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access

21 July 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F

23 May 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Expands U.S. Commercial Team

9 May 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics to Participate in Industry and Investor Conferences in May

26 April 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Appoints Drew Cronin-Fine as Executive Director, Head of U.S. Marketing

31 March 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports Full-Year 2021 Results and Provides Corporate Update

21 March 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Appoints Christopher Wick as Senior Director, Head of U.S. Sales

08 February 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Files Trademark Application for RLF-100TM With the U.S. Patent and Trademark Office

12 January 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Comments on Lawsuit Filed Against It by NeuroRx

30 November 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces Executive Changes

18 November 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Launches Level 1 ADR Program in the United States

24 September 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Reports Half-Year 2021 Results and Provides Corporate Update

26 July 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Relief Therapeutics Announces CHF 15 Million Private Placement